HOTH Hoth Therapeutics
- 0.8490
- +0.0182+2.19%
Hoth Therapeutics News
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Pavell Jeff
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sarnoff David
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Knie Robb
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Linsley Wayne
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Knie Robb
Hoth Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Springer Graig
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sarnoff David
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Pavell Jeff
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Linsley Wayne
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Knie Robb
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sarnoff David
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Springer Graig
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Knie Robb
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Pavell Jeff
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Linsley Wayne
Hoth Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)
Hoth Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(4.2%),Daniel B. Asher(4.2%), etc.
Hoth Therapeutics | D: Filing D
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities
Analysis
Price Target
No Data
No Data